DXCM vs SNN
Dexcom and Smith & Nephew plc, both Healthcare
Dexcom is the larger company at $28B against $13B. On trailing earnings DXCM is the cheaper of the two at a P/E of 33.4 against 38.0, a gap that is only a bargain if the two are growing at similar rates. Over the past year DXCM returned +11% against -24% for SNN. The RyuScore puts DXCM ahead, 73 against 64 out of 100.
| Figure | DXCM | SNN |
|---|---|---|
| Last close | $84.10 | $27.23 |
| Market cap | $28B | $13B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 33.4 | 38.0 |
| 1-year return | +11% | -24% |
| 5-year return | -38% | -16% |
| RyuScoresector-relative, 1–10 | 73/100 | 64/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Dexcom
Revenue of $1.3B in Q2 2026, net income $249M. Its largest reported line is United States, 81% of the disclosed total.
Smith & Nephew plc
Open these two in the interactive comparison to add more names, change the period or see the correlation.